Roche: ESG and Access to Healthcare Custom Case Solution & Analysis

Case Evidence Brief

1. Financial Metrics

• Research and Development Investment: Roche invested approximately 13.7 billion CHF in R&D during 2021, representing one of the highest absolute spends in the pharmaceutical sector.
• Product Portfolio: 32 Roche medicines are included in the World Health Organization Model Lists of Essential Medicines.
• Revenue Concentration: A significant portion of revenue is derived from high-margin oncology and diagnostic segments in high-income markets.
• Market Access: Tiered pricing models are currently applied across various geographic regions to adjust for local purchasing power.

2. Operational Facts

• Global Access Program: Focuses on expanding diagnostic testing for HIV, tuberculosis, and hepatitis in resource-limited settings.
• Supply Chain Requirements: Many Roche oncology products are biologics requiring sophisticated cold-chain logistics and specialized medical infrastructure for administration.
• Regulatory Engagement: Roche maintains active partnerships with the Medicines Patent Pool for specific diagnostic technologies but maintains strict control over oncology IP.
• Manufacturing: Centralized production facilities primarily located in Europe and North America, with limited local manufacturing in low-and-middle-income countries.

3. Stakeholder Positions

• Severin Schwan (CEO): Prioritizes the sustainability of the innovation model, asserting that IP protection is the primary driver for future medical breakthroughs.
• ESG Rating Agencies: Pressuring Roche to improve transparency regarding sub-national pricing and to increase participation in IP sharing initiatives.
• LMIC Governments: Seeking lower price points and technology transfers to build domestic pharmaceutical capabilities.
• Investors: Focused on maintaining high margins while mitigating the reputational risk associated with high drug prices in developing markets.

4. Information Gaps

• Detailed margin analysis for products distributed under the Global Access Program versus commercial segments.
• Specific success rates of local capacity-building initiatives in Sub-Saharan Africa.
• Quantified impact of parallel trade risks if tiered pricing is expanded significantly.

Strategic Analysis

1. Core Strategic Question

• How can Roche expand its footprint in low-and-middle-income countries to meet ESG mandates without compromising the intellectual property framework that funds its R&D-intensive business model?

2. Structural Analysis

Applying the Value Chain lens reveals that Roche's primary bottleneck in LMICs is not just pricing, but the downstream infrastructure required to deliver complex biologics. Porter's Five Forces analysis indicates that while the threat of generic entry is high for small molecules, the high barriers to entry for biosimilars provide Roche a temporary buffer. However, the bargaining power of buyers (governments) is increasing through pooled procurement initiatives. The Jobs-to-be-Done for LMIC health ministries is not just purchasing a vial, but improving population health outcomes with limited diagnostic and clinical capacity.

3. Strategic Options

• Option A: Aggressive Tiered Pricing and Volume Expansion. Drastically reduce prices in LMICs to marginal cost plus distribution. Trade-offs: High risk of product diversion to high-income markets and potential erosion of global reference pricing. Resource Requirements: Enhanced tracking technology and localized distribution partnerships.
• Option B: Selective IP Licensing for Older Oncology Assets. License patents for previous-generation biologics to local manufacturers in exchange for royalties and quality oversight. Trade-offs: Direct creation of future competitors but secures immediate ESG gains and market presence. Resource Requirements: Legal and technical transfer teams to support local manufacturers.
• Option C: Integrated Diagnostics and Treatment Packages. Bundle diagnostic equipment with long-term drug supply agreements at a fixed per-patient cost. Trade-offs: Requires significant upfront capital investment in local clinics. Resource Requirements: Expansion of the Diagnostics division service teams in emerging markets.

4. Preliminary Recommendation

Roche should pursue Option C. This approach utilizes the internal strengths of both the Pharmaceuticals and Diagnostics divisions. By controlling the diagnostic entry point, Roche ensures that its therapies are used appropriately, which justifies the value proposition to local governments and prevents the waste of expensive medicines in systems with poor screening capabilities.

Implementation Roadmap

1. Critical Path

• Month 1-3: Identify three pilot LMIC markets with existing basic oncology infrastructure.
• Month 4-6: Finalize cross-divisional pricing for bundled diagnostic and therapeutic packages.
• Month 7-12: Establish local training centers for healthcare providers to ensure clinical readiness.
• Month 13+: Scale the model to broader geographic regions based on pilot outcomes.

2. Key Constraints

• Regulatory Lag: Approval for new pricing models and diagnostic protocols by local health authorities often takes longer than anticipated.
• Cold-Chain Logistics: The physical inability to transport biologics to rural areas remains a hard ceiling on market penetration.
• Healthcare Workforce: A lack of trained oncologists in target markets limits the total addressable patient population regardless of drug price.

3. Risk-Adjusted Implementation Strategy

The strategy assumes a phased rollout. To mitigate the risk of parallel trade, Roche must implement molecular markers or region-specific packaging for all products sold under the access program. If local clinical capacity fails to meet the required standard within 12 months, the program must pivot from direct drug supply to a primary focus on diagnostic infrastructure development until the system can support complex therapies.

Executive Review and BLUF

1. BLUF

Roche must pivot from a product-centric to a system-centric model in LMICs. The current tension between IP protection and access is a false dichotomy. By integrating Diagnostics and Pharmaceuticals into a single delivery package, Roche can defend its pricing in high-income markets while securing volume in emerging ones. Success depends on building the clinical infrastructure necessary to use Roche products safely. Failure to act will result in increased regulatory pressure and the eventual loss of IP autonomy in these regions.

2. Dangerous Assumption

The analysis assumes that LMIC governments will prioritize oncology spending over primary care or infectious diseases if prices are lowered. If these governments maintain current budget allocations, even a 90 percent price reduction will not result in significant volume growth.

3. Unaddressed Risks

• Reference Pricing Contagion: Large-scale price transparency in LMICs may lead middle-income or even high-income nations to demand similar concessions, threatening core margins. (Probability: High; Consequence: Severe)
• Biosimilar Acceleration: While Roche focuses on infrastructure, competitors may launch biosimilars that do not require the same diagnostic overhead, capturing the market through simplicity. (Probability: Medium; Consequence: Moderate)

4. Unconsidered Alternative

The team did not evaluate the creation of a standalone social enterprise subsidiary. This entity could operate with a different cost structure and brand identity, shielding the parent company from pricing volatility and allowing for more radical experiments in local manufacturing without affecting the Roche master brand.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW